

Antonio Marra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5894234/publications.pdf>

Version: 2024-02-01

33
papers

1,455
citations

623734

14
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

1952
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962.	1.6	353
2	Recent advances in triple negative breast cancer: the immunotherapy era. <i>BMC Medicine</i> , 2019, 17, 90.	5.5	267
3	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54.	5.2	181
4	Evolution of low HER2 expression between early and advanced-stage breast cancer. <i>European Journal of Cancer</i> , 2022, 163, 35-43.	2.8	88
5	Are all cyclin-dependent kinases 4/6 inhibitors created equal?. <i>Npj Breast Cancer</i> , 2019, 5, 27.	5.2	85
6	Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2020, 84, 101963.	7.7	61
7	The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. <i>European Journal of Cancer</i> , 2020, 132, 199-206.	2.8	48
8	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. , 2018, 6, 126.		40
9	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 67.	3.7	39
10	Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 41-49.	2.0	26
11	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. <i>Modern Pathology</i> , 2022, 35, 193-201.	5.5	25
12	Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020, 49, 202-209.	2.2	24
13	Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas. <i>Modern Pathology</i> , 2022, 35, 962-971.	5.5	22
14	Cancer-Causative Mutations Occurring in Early Embryogenesis. <i>Cancer Discovery</i> , 2022, 12, 949-957.	9.4	21
15	Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. <i>Oncologist</i> , 2020, 25, e1732-e1742.	3.7	16
16	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021, 145, 197-209.	2.8	16
17	Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study. <i>Clinical Lung Cancer</i> , 2020, 21, e567-e571.	2.6	15
18	The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. <i>Targeted Oncology</i> , 2018, 13, 333-351.	3.6	14

#	ARTICLE	IF	CITATIONS
19	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169.	7.7	14
20	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	7.0	13
21	Immune Checkpoint Inhibitors in Melanoma and HIV Infection. <i>Open AIDS Journal</i> , 2017, 11, 91-100.	0.5	12
22	Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. <i>European Journal of Cancer</i> , 2020, 139, 92-98.	2.8	12
23	Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 561390.	4.8	12
24	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 166-181.	1.7	10
25	PIK3CA Mutation Assessment in HR+/HER2 ⁻ Metastatic Breast Cancer: Overview for Oncology Clinical Practice. <i>Journal of Molecular Pathology</i> , 2021, 2, 42-54.	1.2	9
26	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 465-484.	2.5	6
27	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2022-003430.	2.5	5
28	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa064.	2.9	4
29	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	7.0	4
30	Toward precision medicine in inflammatory breast cancer. <i>Translational Cancer Research</i> , 2019, 8, S469-S478.	1.0	4
31	What therapies are on the horizon for HER2 positive breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 811-822.	2.4	3
32	Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. <i>European Journal of Cancer</i> , 2021, 157, 40-49.	2.8	3
33	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	6.3	3